COMMUNIQUÉS West-GlobeNewswire

Solésence Reschedules Second Quarter 2026 Conference Call to August 19
11/08/2026
ROMEOVILLE, Ill., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company has [...]
MediPharm Labs Sets Date to Report Second Quarter 2026 Financial Results
11/08/2026
TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based [...]
NORTH Performance Launches Globally with Pre-Sales Site and Founding Athlete Co-Owner Roster
11/08/2026
Next-generation all-in-one performance supplement brand, built on a radical athlete co-ownership model, opens pre-sales ahead of September 2026 product launch DOVER, Del., Aug. 10, 2026 (GLOBE NEWSWIRE) -- NORTH [...]
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
10/08/2026
The reported resubmission of the New Drug Application will initiate a new evaluation of the treatment’s safety and efficacy for potential FDA approval Recently updated FDA guidance, Psychedelic Drugs: Considerations for [...]
HRC Technology Solutions LLC Achieves SOC 1 Type 2 and SOC 2 Type 2 Compliance, Reinforcing Secure, AI-Driven Revenue Cycle Management
10/08/2026
SOUTHLAKE, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- HRC Technology Solutions LLC today announced it has achieved SOC 1 Type 2 and SOC 2 Type 2 compliance, independently assessed by ControlCase as its Qualified Security [...]
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
10/08/2026
Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting Announced a [...]
Mesa Labs Announces First Quarter Results
10/08/2026
LAKEWOOD, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
10/08/2026
- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep [...]
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
10/08/2026
Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 [...]
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer [...]
InspireMD to Announce Second Quarter 2026 Financial Results
10/08/2026
MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced it will issue its [...]
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
10/08/2026
Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval [...]
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
10/08/2026
Expanded collaboration applies multiplex protein profiling across 86,000 additional samples, enabling researchers to move beyond single biomarkers toward a precision-medicine understanding of disease heterogeneity, [...]
TELA Bio Reports Second Quarter 2026 Financial Results
10/08/2026
MALVERN, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
10/08/2026
FREMONT, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for [...]
Bionano Reports Second Quarter 2026 Results and Provides a Business Update
10/08/2026
Conference call today, August 10, 2026, at 4:30 PM ET SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2026. "Our [...]

Pages